SBIO — ALPS Medical Breakthroughs ETF
Data updated: 2026-07-29
SBIO — ALPS Medical Breakthroughs ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $161.79M AUM · 0.50% expense ratio · 87.5% 1-yr return. From SEC regulatory filings.
SBIO Fund Overview
SBIO — ALPS Medical Breakthroughs ETF is a US ETF managed by ALPS ETF Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: ALPS ETF Trust
- Category: United States Health Care Equity
- Assets under management: $161.79M
- 1-year return: 87.5%
- Ticker: SBIO
- SEC CIK: 0001414040
- SEC series ID: S000047823
- Share class ID: C000150206
SBIO Holdings
Top 10 holdings of ALPS Medical Breakthroughs ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Alkermes Plc | 4.48% |
| Kymera Therapeutics Inc | 4.23% |
| Celcuity Inc | 3.92% |
| Mirum Pharmaceuticals Inc | 3.90% |
| Spyre Therapeutics Inc | 3.68% |
| Cg Oncology Inc | 3.35% |
| Apogee Therapeutics Inc | 2.93% |
| Xenon Pharmaceuticals Inc | 2.90% |
| Travere Therapeutics Inc | 2.77% |
| Dianthus Therapeutics Inc | 2.64% |
SBIO Portfolio Allocation
Asset-class allocation of ALPS Medical Breakthroughs ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 100.0% |
SBIO Performance
Total returns for SBIO (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 6.3% |
| 1 year | 87.5% |
| 3 years (annualised) | 21.3% |
| 5 years (annualised) | 3.8% |
SBIO Risk Information
Risk metrics for SBIO, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 17.8%
SBIO Costs and Fees
SBIO costs about $50 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.50%
- Gross expense ratio: 0.50%
- Portfolio turnover: 58%
- Brokerage commissions: 6.20 bps of average net assets (SEC N-CEN)
SBIO Cashflows
Over the 12 months to 2026-02, ALPS Medical Breakthroughs ETF had net inflows of $67.50K, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-02 | −$1.29M |
| 2026-01 | $10.53M |
| 2025-12 | $20.24M |
| 2025-11 | $10.57M |
| 2025-10 | −$21.05M |
| 2025-09 | $1.79M |
SBIO Debt Constituents
No individual debt constituents are reported in ALPS Medical Breakthroughs ETF's latest SEC N-PORT filing.
SBIO Prospectus and SEC Filings
Official ALPS Medical Breakthroughs ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.